# Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

> **NCT02098109** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 100 (actual)

## Conditions studied

- Multiple Myeloma
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** XM02 Filgrastim
- **DRUG:** Filgrastim
- **PROCEDURE:** Apheresis
- **DRUG:** Plerixafor
- **PROCEDURE:** Stem Cell Transplant

## Key facts

- **NCT ID:** NCT02098109
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-20
- **Primary completion:** 2016-06-10
- **Final completion:** 2016-09-18
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2017-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02098109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02098109, "Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02098109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*